Company Overview and News

5
Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q1 2018 Update

2018-05-17 seekingalpha
Fairfax Financial’s largest five stakes are BlackBerry, Resolute Forest Products, Kennedy-Wilson, USG, and Intrepid Potash. They together account for ~85% of the US long assets.

 
Is iShares Emerging Markets Dividend ETF (DVYE) a Hot ETF Right Now?

2018-05-10 zacks
The iShares Emerging Markets Dividend ETF (DVYE - Free Report) made its debut on 02/23/2012, and is a smart beta exchange traded fund that provides broad exposure to the Broad Emerging Market ETFs category of the U.S. equity market.

 
Seaspan Corporation: A Low-Risk 5.48% Yield-To-Maturity For One Year

2018-05-07 seekingalpha
Brief introduction of the company itself, the products of interest to us and how they compare to one another.

 
Seaspan's (SSW) CEO Bing Chen on Q1 2018 Results - Earnings Call Transcript

2018-05-03 seekingalpha
Welcome to the Seaspan Corporation Conference Call to discuss the financial results for the quarter ended March 31, 2018. Hosting the call today are David Sokol, Chairman of Seaspan Corporation, Bing Chen, President and Chief Executive Officer; Peter Curtis, Executive Vice President and Chief Commercial and Technical Officer and David Spivak, Chief Financial Officer, and Ryan Courson, Senior Vice President, Corporate Development.

 
Seaspan Corporation 2018 Q1 - Results - Earnings Call Slides

2018-05-03 seekingalpha
The following slide deck was published by Seaspan Corporation in conjunction with their 2018 Q1 earnings call.

 
6 Short-Term Baby Bonds To Protect You From Interest Rate Risk - Part 1

2018-04-25 seekingalpha
In terms of increased political and interest rate risk, we chose 6 short-term baby bonds (with a maturity date in less than 6 years) to protect your portfolio.

1
4 Well-Covered Preferreds Yielding Over 8%: No K-1, All Going Ex-Dividend Soon

2018-04-15 seekingalpha
They're all cumulative, and 3 of 4 are selling below their $25 call value - the 4th is at $25.03.

 
BRIEF-Seaspan Says Ryan Courson Appointed CFO

2018-04-09 reuters
* SEASPAN CORP - CFO DAVID SPIVAK HAS GIVEN NOTICE THAT HE IS EXERCISING HIS RIGHT TO TERMINATE HIS EMPLOYMENT WITH CO Source text for Eikon: Further company coverage:

1
Seaspan Corp (SSW) Seaspan Acquires GCI Conference (Transcript)

2018-03-20 seekingalpha
Welcome to the Seaspan Corporation Conference Call to discuss Seaspan’s Acquisition of Greater China Intermodal. As a reminder, today’s call is being recorded. Hosting the call today is Bing Chen, President and CEO; of Seaspan Corporation. He is joined by Seaspan Corporation’s CFO; David Spivak. As a reminder, we will be conducting a question-and-answer session and instructions will be given at that time.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...